Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactos...
2018年5月22日 - 9:30PM
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of novel
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on the development
of the first FDA-approved treatment for lactose intolerance, today
announces it will be presenting two posters of additional data from
the Phase 2b trial of RP-G28 at Digestive Disease Week, June 2-5,
2018 in Washington, D.C.
“Both of these posters represent a significant advancement in
the lactose intolerance field. The current management of lactose
intolerant persons focuses on exclusion of dairy products which is
inconvenient and can lead to unintended consequences,” said William
D. Chey, M.D., professor of medicine and co-director of the
Michigan Bowel Control Program at University of Michigan, Ann
Arbor, Mich. “We report an entirely novel approach to
treating lactose intolerance.”
- Poster #1048: “A Novel Tool to Assess Symptoms of Lactose
Intolerance and Define Meaningful Patient Benefit” will be
presented on June 4, 2018.
- Poster #1884: “Improvement of Clinical Symptoms of Lactose
Intolerance with a Novel Prebiotic Galacto-Oligosaccharide,
RP-G28,” will be presented on June 5, 2018.
“As we examine the totality of our Phase 2b trial results, we
are encouraged by the therapeutic potential RP-G28 may have in
treating lactose intolerance,” said Andrew J. Ritter, co-founder
and president of Ritter Pharmaceuticals, Inc. “We continue to build
upon this data in the development of our Phase 3 program, for which
we plan to initiate our first pivotal trial in the second quarter
of 2018.”
About Digestive Disease Week Highlighting the
most relevant, up-to-date and cutting-edge science, Digestive
Disease Week® (DDW) is the largest international gathering of
physicians, researchers and academics in the fields of
gastroenterology, hepatology, endoscopy and gastrointestinal
surgery. DDW is jointly sponsored by the American Association for
the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA) Institute, the American
Society for Gastrointestinal Endoscopy (ASGE), and the Society for
Surgery of the Alimentary Tract (SSAT). In 2018, it is held
from June 2-5 in Washington, D.C. About Ritter
PharmaceuticalsRitter Pharmaceuticals, Inc.
(www.RitterPharma.com, @RitterPharma) develops novel therapeutic
products that modulate the gut microbiome to treat gastrointestinal
diseases. The Company’s lead product candidate, RP-G28, has the
potential to become the first FDA-approved treatment for lactose
intolerance, a condition that affects millions of people worldwide.
RP-G28 has been studied in Phase 2 trials, and is expected to
commence Phase 3 clinical development in the second quarter of
2018. The Company is further exploring the therapeutic potential
that gut microbiome changes may have on treating/preventing a
variety of diseases including: gastrointestinal diseases, cancer,
metabolic, and liver disease.
Forward-Looking StatementsThis press release
may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 that express the
current beliefs and expectations of Ritter Pharmaceuticals’
management, including statements regarding the timing and
commencement of our first Phase 3 clinical trial. Any statements
contained herein that do not describe historical facts are
forward-looking statements that are subject to risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from those discussed in such
forward-looking statements. Factors that could affect our actual
results are included in the periodic reports on Form 10-K and Form
10-Q that we file with the Securities and Exchange Commission.
These forward-looking statements are made only as of the date
hereof, and the Company undertakes no obligation to update or
revise the forward-looking statements, except as otherwise required
by law, whether as a result of new information, future events or
otherwise.
Contacts
Investor Contact:
Shaun Novin
310-203-1000
shaun@ritterpharma.com
Media Contact:
Jules Abraham
CoreIR
917-885-7378
julesa@coreir.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 6 2024 まで 7 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
過去 株価チャート
から 7 2023 まで 7 2024